Genovis: Adding genomics exposure - Redeye
Bildkälla: Stockfoto

Genovis: Adding genomics exposure - Redeye

Redeye comments on Genovis’ decision to acquire the remaining 75% of SEQURNA, viewing it as a logical, synergistic move that leverages its growing net cash and adds exposure to the sizable and growing genomics market.

Redeye comments on Genovis’ decision to acquire the remaining 75% of SEQURNA, viewing it as a logical, synergistic move that leverages its growing net cash and adds exposure to the sizable and growing genomics market.
Börsvärldens nyhetsbrev